Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, and.
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
J Clin Invest. 2020 Dec 1;130(12):6688-6699. doi: 10.1172/JCI141828.
BACKGROUNDData from studies conducted in rodent models have shown that decreased adipose tissue (AT) oxygenation is involved in the pathogenesis of obesity-induced insulin resistance. Here, we evaluated the potential influence of AT oxygenation on AT biology and insulin sensitivity in people.METHODSWe evaluated subcutaneous AT oxygen partial pressure (pO2); liver and whole-body insulin sensitivity; AT expression of genes and pathways involved in inflammation, fibrosis, and branched-chain amino acid (BCAA) catabolism; systemic markers of inflammation; and plasma BCAA concentrations, in 3 groups of participants that were rigorously stratified by adiposity and insulin sensitivity: metabolically healthy lean (MHL; n = 11), metabolically healthy obese (MHO; n = 15), and metabolically unhealthy obese (MUO; n = 20).RESULTSAT pO2 progressively declined from the MHL to the MHO to the MUO group, and was positively associated with hepatic and whole-body insulin sensitivity. AT pO2 was positively associated with the expression of genes involved in BCAA catabolism, in conjunction with an inverse relationship between AT pO2 and plasma BCAA concentrations. AT pO2 was negatively associated with AT gene expression of markers of inflammation and fibrosis. Plasma PAI-1 increased from the MHL to the MHO to the MUO group and was negatively correlated with AT pO2, whereas the plasma concentrations of other cytokines and chemokines were not different among the MHL and MUO groups.CONCLUSIONThese results support the notion that reduced AT oxygenation in individuals with obesity contributes to insulin resistance by increasing plasma PAI-1 concentrations and decreasing AT BCAA catabolism and thereby increasing plasma BCAA concentrations.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants K01DK109119, T32HL130357, K01DK116917, R01ES027595, P42ES010337, DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK052574 (Digestive Disease Research Center), and UL1TR002345 (Clinical and Translational Science Award); NIH Shared Instrumentation Grants S10RR0227552, S10OD020025, and S10OD026929; and the Foundation for Barnes-Jewish Hospital.
来自啮齿动物模型的研究数据表明,脂肪组织(AT)氧合作用降低与肥胖引起的胰岛素抵抗的发病机制有关。在这里,我们评估了 AT 氧合作用对人体 AT 生物学和胰岛素敏感性的潜在影响。
我们评估了皮下 AT 氧分压(pO2);肝脏和全身胰岛素敏感性;AT 中涉及炎症、纤维化和支链氨基酸(BCAA)分解代谢的基因和途径的表达;全身炎症标志物;以及在严格按肥胖和胰岛素敏感性分层的 3 组参与者中,血浆 BCAA 浓度:代谢健康的瘦(MHL;n = 11)、代谢健康的肥胖(MHO;n = 15)和代谢不健康的肥胖(MUO;n = 20)。
AT pO2 从 MHL 到 MHO 再到 MUO 组逐渐下降,与肝和全身胰岛素敏感性呈正相关。AT pO2 与参与 BCAA 分解代谢的基因表达呈正相关,同时 AT pO2 与血浆 BCAA 浓度呈负相关。AT pO2 与 AT 炎症和纤维化标志物的基因表达呈负相关。血浆 PAI-1 从 MHL 到 MHO 再到 MUO 组增加,与 AT pO2 呈负相关,而血浆中其他细胞因子和趋化因子的浓度在 MHL 和 MUO 组之间没有差异。
这些结果支持这样一种观点,即肥胖个体 AT 氧合作用的降低通过增加血浆 PAI-1 浓度和降低 AT BCAA 分解代谢,从而增加血浆 BCAA 浓度,导致胰岛素抵抗。
ClinicalTrials.gov NCT02706262。
本研究由 NIH 授予的 K01DK109119、T32HL130357、K01DK116917、R01ES027595、P42ES010337、DK56341(营养肥胖研究中心)、DK20579(糖尿病研究中心)、DK052574(消化疾病研究中心)和 UL1TR002345(临床和转化科学奖);NIH 共享仪器拨款 S10RR0227552、S10OD020025 和 S10OD026929;以及 Barnes-Jewish 医院基金会。